Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.
about
COX-2 Inhibitors and Gastric CancerThe use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksA review of the gastrointestinal safety data--a gastroenterologist's perspective.Prevention of chronic NSAID induced upper gastrointestinal toxicity.Towards a mechanism-based approach to pain management in osteoarthritisNonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage.Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries.Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidanceProton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review.Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks.Imprudent Gastro-protective Approach in Majority of Specialists' Clinics of a Tertiary Hospital.Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain.Dosage effects of histamine-2 receptor antagonist on the primary prophylaxis of non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers: a retrospective cohort study.Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.Abdominal discomfort in patients with rheumatoid arthritis is associated with physical and mental function, self-reported disease activity, and use of anti-inflammatory medication.
P2860
Q27692701-C16DEB99-1BF9-4C94-AA0F-F4FCF5D40F3BQ30415171-8994CD21-66F9-4553-9FF6-65721884CF35Q30629677-DBC43E6A-32E0-4B59-84C1-122677C8F498Q33560647-BE9B2101-5D7C-4F25-BAE2-66B7F3879222Q33978682-1D30A790-7133-4D52-8DF5-3148531D188CQ34120813-03BD2DF1-7EC8-4E46-A741-D12528ACD0A6Q34387174-7A557EFE-D32F-4D4E-B197-087D79EAF42AQ34592490-0DBE0703-D299-4E12-8E0A-BDFD15DF72CDQ34655792-E9E03914-5D48-4FC2-8036-6816FEDDAC3CQ36246550-E897F9E6-1E9F-4CB2-B91A-80CB5077BF91Q36942298-F2389BBB-EFED-4B08-A762-800EFE98601BQ38941017-A59A1CE0-7F79-4A5B-BA98-16BDBB63D401Q39804588-0FEF3D41-96D7-4BC3-A788-0977A9B60A39Q39844782-4A9D1702-360A-4EA3-A637-74C6A91A868BQ44452482-FD7D72EE-BB43-42EC-92D5-86B9499B4870Q49502634-8858C312-EFF3-4E4B-B8D2-6D2875E0A373Q50714333-EFB394EE-08AA-4F56-BA44-B4F612C5E9D0
P2860
Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prevention of NSAID-related up ...... otection and COX-2 inhibitors.
@en
Prevention of NSAID-related up ...... otection and COX-2 inhibitors.
@nl
type
label
Prevention of NSAID-related up ...... otection and COX-2 inhibitors.
@en
Prevention of NSAID-related up ...... otection and COX-2 inhibitors.
@nl
prefLabel
Prevention of NSAID-related up ...... otection and COX-2 inhibitors.
@en
Prevention of NSAID-related up ...... otection and COX-2 inhibitors.
@nl
P2093
P2860
P356
P1476
Prevention of NSAID-related up ...... otection and COX-2 inhibitors.
@en
P2093
Alaa Rostom
Angel Lanas
Catherine Dube
Emilie Jolicoeur
Katherine Muir
P2860
P356
10.2147/DHPS.S4334
P407
P577
2009-10-28T00:00:00Z